Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
Abstract
The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that canagliflozin, which provides significant weight loss ability, improves the quality of life and satisfaction with physical and emotional health in patients with diabetes compared with sitagliptin.
About the Authors
Nina A. Petunina
Sechenov First Moscow State Medical University
Russian Federation
MD, PhD, Professor
Competing Interests: No conflict of interests
Russian Federation
MD, PhD, Professor
Competing Interests: No conflict of interests
Anna L. Terekhova
Sechenov First Moscow State Medical University
Russian Federation
MD, PhD, assistant lecturer
Competing Interests: No conflict of interests
Russian Federation
MD, PhD, assistant lecturer
Competing Interests: No conflict of interests
Ekaterina V. Goncharova
Sechenov First Moscow State Medical University
Russian Federation
MD, assistant lecturer
Competing Interests: No conflict of interests
Russian Federation
MD, assistant lecturer
Competing Interests: No conflict of interests
References
1. Williamson DA, Rejeski J, Lang W, et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163-171. doi: 10.1001/archinternmed.2008.544
2. Davies M, Speight J. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012;14(10):882-892. doi: 10.1111/j.1463-1326.2012.01595.x
3. Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121(5):94-107. doi: 10.3810/pgm.2009.09.2056
4. Proper KI. Short term effect of feedback on fitness and health measurements on self reported appraisal of the stage of change. Br J Sports Med. 2003;37(6):529-534. doi: 10.1136/bjsm.37.6.529
5. Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes Rev. 2001;2(3):173-182. doi: 10.1046/j.1467-789x.2001.00032.x
6. Grandy S, Fox KM, Bazata DD. Association of Self-Reported Weight Change and Quality of Life, and Exercise and Weight Management Behaviors Among Adults with Type 2 Diabetes Mellitus: The SHIELD Study. Cardiol Res Pract. 2012;2012:892564. doi: 10.1155/2012/892564
7. Fine JT. A Prospective Study of Weight Change and Health-Related Quality of Life in Women. Jama. 1999;282(22):2136. doi: 10.1001/jama.282.22.2136
8. Kroenke CH, Kubzansky LD, Adler N, Kawachi I. Prospective change in health-related quality of life and subsequent mortality among middle-aged and older women. Am J Public Health. 2008;98(11):2085-2091. doi: 10.2105/AJPH.2007.114041
9. Blake CE, Hebert JR, Lee DC, et al. Adults with greater weight satisfaction report more positive health behaviors and have better health status regardless of BMI. J Obes. 2013;2013:291371. doi: 10.1155/2013/291371
10. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582-2592. doi: 10.1007/s00125-013-3039-1
11. Cefalu WT, Leiter LA, Yoon K-H, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet. 2013;382(9896):941-950. doi: 10.1016/s0140-6736(13)60683-2
12. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508-2515. doi: 10.2337/dc12-2491
13. Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37. doi: 10.1186/1472-6823-14-37
14. Stenlof K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163-175. doi: 10.1185/03007995.2013.850066
15. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16(5):467-477. doi: 10.1111/dom.12273
16. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013;41(2):72-84. doi: 10.3810/hp.2013.04.1020
17. Wilding JP, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications. 2015;29(3):438-444. doi: 10.1016/j.jdiacomp.2014.12.016
18. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38(3):403-411. doi: 10.2337/dc14-1237
19. Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70(10):1149-1158. doi: 10.1007/s00228-014-1730-x
20. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67(12):1267-1282. doi: 10.1111/ijcp.12322
21. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15(5):463-473. doi: 10.1111/dom.12090
22. Schernthaner G, Gross J, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-2515. Diabetes Care. 2013;36(12):4172-4172. doi: 10.2337/dc13-er12a
23. Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126(3):7-15. doi: 10.3810/pgm.2014.05.2752
24. Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57(11):1153-1160. doi: 10.1016/j.jclinepi.2004.04.004
Supplementary files
Review
For citations:
Petunina N.A., Terekhova A.L., Goncharova E.V. Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor. Diabetes mellitus. 2016;19(6):511-517. (In Russ.)
Views:
626
Email this article 
